COVID-19: Viral Pneumonia – Understanding Disease Presentation, Risk Factors and Healthcare Utilization, Including Ventilator and Extracorporeal Membrane Oxygenation (COVID-19: Pneumonia Complications)

Study identification

• EU PAS number:
  EUPAS34494
• Study ID:
  34495
• Official title and acronym:
  COVID-19: Viral Pneumonia – Understanding Disease Presentation, Risk Factors and Healthcare Utilization, Including Ventilator and Extracorporeal Membrane Oxygenation (COVID-19: Pneumonia Complications)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The coronavirus disease (COVID-19) has reported symptoms as fever, cough, fatigue headache, pneumonia, diarrhea, hemoptysis and dyspnea.1 Pneumonia and consequences thereof are fatal to many of the critically-ill patients. 2Whereas multiple papers have attempted to describe the radiographic differences between COVID-19 pneumonia and other viral pneumonias, differentiating between viral pneumonia and bacterial pneumonia at patient admission is difficult, even for experienced physicians, yet alone differentiating between COVID-19 viral and all other viral pneumonias. 3 4 Large-scale analysis to evaluate patient comorbidities, demographics and risk factors for viral pneumonia, as compared to other pneumonia types, has not been well documented. This study is designed to further our understanding of viral pneumonia to help healthcare systems deal with the COVID-19 pandemic.The rationale for conducting this study is as follows: due to the potentially large COVID-19 population requiring ventilation support, there is a risk that the US healthcare system might be overwhelmed. Models to help understand patients at greater risk for increased healthcare needs or mortality may thus help with policy planning, decisions and treatment.This study will be conducted using the Mercy Electronic Healthcare Data - This data is uniquely fit for purpose as it contains, among other common variables, information such as spirometry data, detailed vitals, exact time when ventilator use is ordered and started.
• Study status:
  Planned

Research institutions and networks

Institutions

Mercy Healthcare System

Study timelines

Date when funding contract was signed

Planned:23/03/2020

Study start date

Planned:23/03/2020

Date of final study report

Planned:31/05/2020

Sources of funding

Pharmaceutical company and other private sector 

Other

More details on funding

Johnson & Johnson, Mercy Healthcare

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable